Chinese biotech startup GenFleet Therapeutics has secured nearly 400 million yuan ($58 million) in a Series B round of financing jointly led by Beijing-based alternative asset management firm CDH Investments, and a healthcare industry fund of government-led Shenzhen Capital Group.
Shenzhen-based South China Venture Capital, and Chinese venture capital firm Panlin Capital participated in the investment, according to a statement on March 8.
